Tuesday, December 13, 2011 « Back
Teva to Host 2012 Business Outlook Conference Call

JERUSALEM--(BUSINESS WIRE)--Dec. 13, 2011-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will host a conference call and live webcast on Wednesday, December 21, 2011 at 8:30 a.m. ET to communicate its 2012 business outlook. A Question & Answer session will follow.

In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States and Canada 866-770-7120; International 1-617-213-8065 and enter passcode 23520783.

A live webcast of the call will also be available on Teva's website at: www.tevapharm.com, under Investor Relations Events and Presentations. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company's website. The replay can also be accessed until December 28, 2011, at 11:59 p.m. ET by calling 888-286-8010 or 1-617-801-6888. The conference ID is 71642627.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 47,000 people around the world and reached $16.1 billion in net sales in 2010.

Source: Teva Pharmaceutical Industries Ltd.

IR:
Teva Pharmaceutical Industries Ltd.
Elana Holzman, 972 (3) 926-7554
or
Teva North America
Kevin C. Mannix, 215-591-8912
or
PR:
Teva Pharmaceutical Industries Ltd.
Yossi Koren, 972 (3) 926-7687
or
Teva North America
Denise Bradley, 215-591-8974